bioAffinity Technologies Inc. (BIAF): Price and Financial Metrics
GET POWR RATINGS... FREE!
BIAF Stock Price Chart Interactive Chart >
BIAF Price/Volume Stats
| Current price | $1.58 | 52-week high | $15.55 |
| Prev. close | $1.68 | 52-week low | $1.31 |
| Day low | $1.53 | Volume | 25,700 |
| Day high | $1.68 | Avg. volume | 1,524,053 |
| 50-day MA | $1.97 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 4.31M |
Latest BIAF News From Around the Web
Below are the latest news stories about BIOAFFINITY TECHNOLOGIES INC that investors may wish to consider to help them evaluate BIAF as an investment opportunity.
bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate CommunicationsSAN ANTONIO, February 13, 2023--bioAffinity Technologies announces commercialization team for innovative CyPath® Lung screening test for early-stage lung cancer. |
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory ResearchSAN ANTONIO, January 24, 2023--bioAffinity Technologies announces publication of the results of its clinical trial for its CyPath® Lung cancer diagnostic in Respiratory Research. |
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer TreatmentsSAN ANTONIO, January 04, 2023--bioAffinity Technologies received Notice of Allowance for a U.S. patent protecting novel compounds for specific delivery of cancer treatments. |
Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)Argus Research, an independent investment research firm, has launched Equity Research Report coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF) |
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical BenchSAN ANTONIO, December 15, 2022--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment, today announced that they have made a key promotion and additions to their staff. |
BIAF Price Returns
| 1-mo | -23.30% |
| 3-mo | -6.51% |
| 6-mo | -41.91% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -1.25% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...